Withdrawals due to adverse events · Patients with active Crohn's disease
Two infusions of natalizumab (6 mg/kg) showed no clear difference in withdrawal due to adverse events up to week 12 compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse outcomes · Participants with active Crohn's disease despite current treatment with infliximab
Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in withdrawal due to adverse events up to week 10 compared with placebo and two infusions of infliximab (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
One infusion of natalizumab (300 mg or 3 mg/kg) showed no clear difference in withdrawal due to adverse events up to week 12 compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with Crohn's disease (mixed disease activity population with clinical response at baseline)
It is very uncertain whether infliximab changes withdrawal due to adverse events (at 32‐54 weeks) compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Induction of Remission in Medically Refractory Crohn's Disease
It is very uncertain whether summary of findings table ‐ Stem Cell changes withdrawal due to adverse events compared with placebo or Control (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with inflammatory bowel disease
1 finding from 1 review
Withdrawals due to adverse events · people with inflammatory bowel disease
1 finding from 1 review
Withdrawals due to adverse events · people with inflammatory bowel disease
1 finding from 1 review
Withdrawals due to adverse events · people with inflammatory bowel disease
It is very uncertain whether low FODMAP diet changes withdrawal due to adverse events compared with sham diet (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with inflammatory bowel disease
1 finding from 1 review
Withdrawals due to adverse events · people with inflammatory bowel disease
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
Antibiotic with anti‐TNF showed no clear difference in withdrawal due to adverse events compared with placebo with anti‐TNF (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
Antibiotic showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review